DK2963024T3 - Krystallinske methylthioniniumchloridhydrater - del 2 - Google Patents
Krystallinske methylthioniniumchloridhydrater - del 2 Download PDFInfo
- Publication number
- DK2963024T3 DK2963024T3 DK15176967.6T DK15176967T DK2963024T3 DK 2963024 T3 DK2963024 T3 DK 2963024T3 DK 15176967 T DK15176967 T DK 15176967T DK 2963024 T3 DK2963024 T3 DK 2963024T3
- Authority
- DK
- Denmark
- Prior art keywords
- methylthioninium chloride
- methylthioninium
- crystalline
- powder
- chloride dihydrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Steroid Compounds (AREA)
Claims (6)
1. Krystallinsk methylthioniniumchloridmonohydrat som form E, der har de følgende karakteristiske peaks i et pulverrøntgendiffraktionsmønster (ved anvendelse af CuKa som strålingskilden, ved en
bølgelængde på 1,54180 Å):
2. Forbindelse ifølge krav 1, som har de følgende karakteristiske peaks i et pulverrøntgendiffraktionsmønster (ved anvendelse af CuKa som strålingskilden, ved en bølgelængde på 1,54180 Å):
eller viser ikke nogen termisk hændelse op til nedbrydningstemperaturen på 220 °C ved opvarmning ved en rate på 100°C pr. minut i en differentiel scan-ningskalorimetri.
3. Fremgangsmåde til fremstilling af methylthioniniumchloridmonohydrat i form E ifølge krav 1 eller krav 2, hvor: vand-indeholdende methylthioniniumchlorid eller en blanding af flere hydrater eller et specifikt hydrat af methylthioniniumchlorid suspenderes og omrøres ved en omgivelsestemperatur i et tørt opløsningsmiddel, fortrinsvis isopro-panol, for at generere form E; hvor faststoffet isoleres ved filtrering; og det resterende opløsningsmiddel fjernes fra faststoffet ved enten vakuumtørring eller rensning med tør gas.
4. Farmaceutisk sammensætning, som omfatter methylthioniniumchloridmo-nohydrat i form E ifølge krav 1 eller krav 2 og eventuelt et farmaceutisk acceptabelt bærestof, hjælpestof eller fortyndingsmiddel.
5. Methylthioniniumhloridmonohydrat i form E ifølge krav 1 eller krav 2 til anvendelse i en fremgangsmåde til behandling af menneske- eller dyrekroppen ved terapi.
6. Methylthioniniumchloridmonohydrat i form E ifølge krav 1 eller krav 2 til anvendelse i en fremgangsmåde til behandling af en sygdomstilstand, for eksempel inden for behandlingen af en tauopati, Alzheimers sygdom (AD), hudkræft, melanom, hepatitis C, HIV eller vestnilvirus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24539109P | 2009-09-24 | 2009-09-24 | |
| EP10771516.1A EP2480541B1 (en) | 2009-09-24 | 2010-09-23 | Crystalline methylthionium chloride (methylene blue) hydrates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2963024T3 true DK2963024T3 (da) | 2018-10-08 |
Family
ID=43415329
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10771516.1T DK2480541T3 (da) | 2009-09-24 | 2010-09-23 | Krystallinske methylthioniniumchlorid (methylenblåt)-hydrater |
| DK18170358.8T DK3378856T3 (da) | 2009-09-24 | 2010-09-23 | Krystallinske methylthioniniumchlorid-hydrater |
| DK20203173.8T DK3792254T3 (da) | 2009-09-24 | 2010-09-23 | Krystallinske methylthioninium-chloridhydrater |
| DK15176967.6T DK2963024T3 (da) | 2009-09-24 | 2010-09-23 | Krystallinske methylthioniniumchloridhydrater - del 2 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10771516.1T DK2480541T3 (da) | 2009-09-24 | 2010-09-23 | Krystallinske methylthioniniumchlorid (methylenblåt)-hydrater |
| DK18170358.8T DK3378856T3 (da) | 2009-09-24 | 2010-09-23 | Krystallinske methylthioniniumchlorid-hydrater |
| DK20203173.8T DK3792254T3 (da) | 2009-09-24 | 2010-09-23 | Krystallinske methylthioninium-chloridhydrater |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8765742B2 (da) |
| EP (4) | EP2963024B1 (da) |
| JP (1) | JP5806217B2 (da) |
| KR (3) | KR20120099409A (da) |
| CN (2) | CN105061358A (da) |
| AU (1) | AU2010299571B2 (da) |
| BR (4) | BR122019022631B8 (da) |
| CA (4) | CA3077911C (da) |
| DK (4) | DK2480541T3 (da) |
| ES (4) | ES2557318T3 (da) |
| FI (1) | FI3792254T3 (da) |
| HK (2) | HK1167653A1 (da) |
| HR (3) | HRP20231201T1 (da) |
| MX (2) | MX2012003083A (da) |
| MY (1) | MY159782A (da) |
| PL (4) | PL2963024T3 (da) |
| PT (4) | PT2963024T (da) |
| SG (1) | SG10201408584UA (da) |
| SI (4) | SI2963024T1 (da) |
| WO (1) | WO2011036558A2 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| ES2659091T3 (es) * | 2009-09-24 | 2018-03-13 | Wista Laboratories Ltd. | Pentahidrato de cloruro de metiltioninio, preparación y uso farmacéutico del mismo |
| CN109846862A (zh) | 2012-10-25 | 2019-06-07 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| CN110305095A (zh) | 2013-10-22 | 2019-10-08 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
| US10765755B1 (en) | 2013-11-20 | 2020-09-08 | University Of South Florida | Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies |
| WO2018019823A1 (en) | 2016-07-25 | 2018-02-01 | Wista Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
| US20190240194A1 (en) | 2016-08-31 | 2019-08-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| US10561612B2 (en) | 2017-07-20 | 2020-02-18 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and ibuprofen |
| KR20210071943A (ko) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| WO2024063700A1 (en) | 2022-09-21 | 2024-03-28 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| PL2322517T3 (pl) | 2004-09-23 | 2019-09-30 | Wista Laboratories Ltd. | Sposoby syntezy chemicznej i oczyszczania związków diaminofenotiazyniowych, w tym chlorku metylotioniny (MTC) |
| PL2013191T6 (pl) * | 2006-03-29 | 2019-07-31 | Wista Laboratories Ltd. | Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie |
| ES2667002T3 (es) * | 2006-03-29 | 2018-05-09 | Wista Laboratories Ltd. | Inhibidores de la agregación de proteínas |
| CN101631780A (zh) * | 2007-04-03 | 2010-01-20 | 普罗瑟塔生物谐成公司 | 用于抗病毒治疗的吩噻嗪衍生物 |
| US7603854B2 (en) | 2007-04-10 | 2009-10-20 | Illinois Tool Works Inc. | Pneumatically self-regulating valve |
-
2010
- 2010-09-23 FI FIEP20203173.8T patent/FI3792254T3/fi active
- 2010-09-23 SI SI201031765T patent/SI2963024T1/sl unknown
- 2010-09-23 DK DK10771516.1T patent/DK2480541T3/da active
- 2010-09-23 ES ES10771516.1T patent/ES2557318T3/es active Active
- 2010-09-23 EP EP15176967.6A patent/EP2963024B1/en active Active
- 2010-09-23 PL PL15176967T patent/PL2963024T3/pl unknown
- 2010-09-23 ES ES15176967.6T patent/ES2689029T3/es active Active
- 2010-09-23 SG SG10201408584UA patent/SG10201408584UA/en unknown
- 2010-09-23 DK DK18170358.8T patent/DK3378856T3/da active
- 2010-09-23 US US13/497,686 patent/US8765742B2/en active Active
- 2010-09-23 CN CN201510501874.XA patent/CN105061358A/zh active Pending
- 2010-09-23 EP EP20203173.8A patent/EP3792254B1/en active Active
- 2010-09-23 KR KR1020127009853A patent/KR20120099409A/ko active Application Filing
- 2010-09-23 PT PT15176967T patent/PT2963024T/pt unknown
- 2010-09-23 SI SI201031101T patent/SI2480541T1/sl unknown
- 2010-09-23 SI SI201032051T patent/SI3378856T1/sl unknown
- 2010-09-23 DK DK20203173.8T patent/DK3792254T3/da active
- 2010-09-23 PL PL10771516T patent/PL2480541T3/pl unknown
- 2010-09-23 CA CA3077911A patent/CA3077911C/en active Active
- 2010-09-23 AU AU2010299571A patent/AU2010299571B2/en active Active
- 2010-09-23 PT PT181703588T patent/PT3378856T/pt unknown
- 2010-09-23 BR BR122019022631A patent/BR122019022631B8/pt active IP Right Grant
- 2010-09-23 HR HRP20231201TT patent/HRP20231201T1/hr unknown
- 2010-09-23 KR KR1020177013764A patent/KR20170061177A/ko active Search and Examination
- 2010-09-23 ES ES20203173T patent/ES2960761T3/es active Active
- 2010-09-23 CA CA2773305A patent/CA2773305C/en active Active
- 2010-09-23 DK DK15176967.6T patent/DK2963024T3/da active
- 2010-09-23 PT PT107715161T patent/PT2480541E/pt unknown
- 2010-09-23 BR BR112012006638-2A patent/BR112012006638B1/pt active IP Right Grant
- 2010-09-23 WO PCT/IB2010/002526 patent/WO2011036558A2/en active Application Filing
- 2010-09-23 MX MX2012003083A patent/MX2012003083A/es active IP Right Grant
- 2010-09-23 MY MYPI2012001322A patent/MY159782A/en unknown
- 2010-09-23 BR BR122019022628A patent/BR122019022628B8/pt active IP Right Grant
- 2010-09-23 JP JP2012530357A patent/JP5806217B2/ja active Active
- 2010-09-23 ES ES18170358T patent/ES2847003T3/es active Active
- 2010-09-23 CA CA3141737A patent/CA3141737C/en active Active
- 2010-09-23 PL PL18170358T patent/PL3378856T3/pl unknown
- 2010-09-23 BR BR122019022612A patent/BR122019022612B8/pt active IP Right Grant
- 2010-09-23 PL PL20203173.8T patent/PL3792254T3/pl unknown
- 2010-09-23 MX MX2015008552A patent/MX355627B/es unknown
- 2010-09-23 PT PT202031738T patent/PT3792254T/pt unknown
- 2010-09-23 EP EP10771516.1A patent/EP2480541B1/en active Active
- 2010-09-23 SI SI201032134T patent/SI3792254T1/sl unknown
- 2010-09-23 CA CA3004822A patent/CA3004822C/en active Active
- 2010-09-23 EP EP18170358.8A patent/EP3378856B1/en active Active
- 2010-09-23 HR HRP20181567TT patent/HRP20181567T2/hr unknown
- 2010-09-23 KR KR1020187022958A patent/KR20180094126A/ko not_active Application Discontinuation
- 2010-09-23 CN CN201080053178.2A patent/CN102666511B/zh active Active
-
2012
- 2012-08-29 HK HK12108434.3A patent/HK1167653A1/xx unknown
- 2012-08-29 HK HK16101978.6A patent/HK1213897A1/zh unknown
-
2021
- 2021-01-19 HR HRP20210086TT patent/HRP20210086T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2963024T3 (da) | Krystallinske methylthioniniumchloridhydrater - del 2 | |
| DK2480540T3 (da) | Methylthioniniumchlorid-pentahydrat, fremstilling og farmaceutisk anvendelse deraf | |
| AU2017228644B2 (en) | Crystalline methylthionium chloride (methylene blue) hydrates | |
| AU2014253566A1 (en) | Crystalline methylthionium chloride (methylene blue) hydrates |